Turning Point Therapeutics Inc. (TPTX) NASDAQ

$76.01 - (-)

Market Cap: -

As of 08/16/22 12:00 AM EDT. Market closed.

(TPTX)

Turning Point Therapeutics Inc. (TPTX)
NASDAQ

$76.01
- (-)

Market Cap: -

As of 08/16/22 12:00 AM EDT. Market closed.

Add to Portfolio

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. ... read more

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO Compensation (Base)
$329,442
CEO Compensation (Total)
$8.66M
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
142
CEO Compensation (Base)
$329,442
CEO Compensation (Total)
$8.66M
Address
.
PRICE CHART FOR TURNING POINT THERAPEUTICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$76.01
Days Range
$75.98 - $76.01
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
50,074,277
Open
-
Previous Close
$76.01
Days Range
$75.98 - $76.01
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
50,074,277
FINANCIAL STATEMENTS FOR TURNING POINT THERAPEUTICS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR TURNING POINT THERAPEUTICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
George SimeonDirectorAug 17, 2022 Option Exercise$76.002,253,660171,278,1600Aug 17, 2022, 04:40 PM
Alles Mark JDirectorAug 17, 2022 Option Exercise$76.002,000152,0000Aug 17, 2022, 04:32 PM
TOMBESI PAOLOEVP & Chief Financial OfficerAug 17, 2022 Option Exercise$76.0029,7782,263,1280Aug 17, 2022, 04:31 PM
Hirmand MohammadEVP and Chief Medical OfficerAug 17, 2022 Option Exercise$76.0041,2843,137,5840Aug 17, 2022, 04:26 PM
Countouriotis AthenaPresident & CEOAug 17, 2022 Option Exercise$76.00110,9598,432,8840Aug 17, 2022, 04:23 PM
TOMBESI PAOLOEVP & Chief Financial OfficerJul 27, 2022 Sale$74.941,18388,65428,700Jul 29, 2022, 04:18 PM
Reich SiegfriedEVP & Chief Scientific OfficerFeb 09, 2022 Sale$36.3039714,4113,448Feb 11, 2022, 06:10 PM
Partridge Andrew JohnEVP & Chief Commercial OfficerFeb 09, 2022 Sale$36.302218,02222,078Feb 11, 2022, 06:09 PM
North AnnetteEVP & General CounselFeb 09, 2022 Sale$36.3066924,28511,696Feb 11, 2022, 06:09 PM
Hirmand MohammadEVP & Chief Medical OfficerFeb 09, 2022 Sale$36.3066924,2856,838Feb 11, 2022, 06:08 PM
Countouriotis AthenaPresident & CEOFeb 09, 2022 Sale$36.302,971107,84747,930Feb 11, 2022, 06:07 PM
North AnnetteEVP, General Counsel & Secty.Aug 30, 2021 Option Exercise$17.0010,000170,00022,365Aug 31, 2021, 05:26 PM
North AnnetteEVP, General Counsel & Secty.Aug 30, 2021 Sale$80.0010,000800,00012,365Aug 31, 2021, 05:26 PM
Partridge Andrew JohnEVP & Chief Commercial OfficerJul 14, 2021 Sale$74.901,869139,98821,767Jul 15, 2021, 05:53 PM
Alles Mark JDirectorJun 21, 2021 Buy$81.342,000162,6802,000Jun 21, 2021, 09:14 PM
Baker Brian LeeSVP of Finance and Admin.Mar 23, 2021 Option Exercise$4.6728,435132,90632,551Mar 24, 2021, 09:54 PM
Baker Brian LeeSVP of Finance and Admin.Mar 23, 2021 Sale$100.6528,4352,862,08227,632Mar 24, 2021, 09:54 PM
North AnnetteEVP, General Counsel & Secty.Mar 08, 2021 Option Exercise$17.0020,000340,00026,483Mar 09, 2021, 07:26 PM
North AnnetteEVP, General Counsel & Secty.Mar 08, 2021 Sale$109.8020,0002,195,93925,983Mar 09, 2021, 07:26 PM
Reich SiegfriedEVP & Chief Scientific OfficerMar 04, 2021 Option Exercise$51.2835,5501,823,00439,395Mar 05, 2021, 08:56 PM
Reich SiegfriedEVP & Chief Scientific OfficerMar 04, 2021 Sale$105.0435,5503,734,07536,390Mar 05, 2021, 08:56 PM
Countouriotis AthenaPresident & CEOFeb 11, 2021 Option Exercise$3.208,94228,61459,137Feb 11, 2021, 08:28 PM
Countouriotis AthenaPresident & CEOFeb 10, 2021 Option Exercise$3.2025,39281,25475,587Feb 11, 2021, 08:28 PM
Countouriotis AthenaPresident & CEOFeb 09, 2021 Option Exercise$3.2025,66682,13175,861Feb 11, 2021, 08:28 PM
Countouriotis AthenaPresident & CEOFeb 11, 2021 Sale$137.388,9421,228,44654,818Feb 11, 2021, 08:28 PM
Countouriotis AthenaPresident & CEOFeb 10, 2021 Sale$136.3125,3923,461,11674,562Feb 11, 2021, 08:28 PM
Countouriotis AthenaPresident & CEOFeb 09, 2021 Sale$138.6825,6663,559,47569,661Feb 11, 2021, 08:28 PM
North AnnetteEVP, General Counsel & Secty.Feb 02, 2021 Option Exercise$17.009,016153,2729,016Feb 02, 2021, 09:50 PM
North AnnetteEVP, General Counsel & Secty.Feb 01, 2021 Option Exercise$17.0015,984271,72815,984Feb 02, 2021, 09:50 PM
North AnnetteEVP, General Counsel & Secty.Feb 02, 2021 Sale$129.889,0161,170,9898,616Feb 02, 2021, 09:50 PM
North AnnetteEVP, General Counsel & Secty.Feb 01, 2021 Sale$123.6515,9841,976,37414,354Feb 02, 2021, 09:50 PM
Larson YiEVP & Chief Financial OfficerFeb 01, 2021 Option Exercise$54.0315,702848,37918,406Feb 02, 2021, 09:47 PM
Larson YiEVP & Chief Financial OfficerFeb 02, 2021 Option Exercise$54.0314,298772,52117,002Feb 02, 2021, 09:47 PM
Larson YiEVP & Chief Financial OfficerFeb 01, 2021 Sale$123.6215,7021,941,10513,623Feb 02, 2021, 09:47 PM
Larson YiEVP & Chief Financial OfficerFeb 02, 2021 Sale$130.1414,2981,860,81316,002Feb 02, 2021, 09:47 PM
Baker Brian LeeSVP of Finance and Admin.Jan 07, 2021 Option Exercise$4.6728,438132,91832,246Jan 08, 2021, 09:08 PM
Baker Brian LeeSVP of Finance and Admin.Jan 07, 2021 Sale$122.2631,2383,819,09029,446Jan 08, 2021, 09:08 PM
Hirmand MohammadEVP and Chief Medical OfficerJan 04, 2021 Option Exercise$54.738,747478,7239,331Jan 05, 2021, 09:03 PM
Hirmand MohammadEVP and Chief Medical OfficerJan 05, 2021 Option Exercise$54.731,25368,5771,537Jan 05, 2021, 09:03 PM
Hirmand MohammadEVP and Chief Medical OfficerJan 05, 2021 Sale$120.001,253150,360284Jan 05, 2021, 09:03 PM
Hirmand MohammadEVP and Chief Medical OfficerJan 04, 2021 Sale$120.499,0471,090,0469,031Jan 05, 2021, 09:03 PM
Cui Jingrong JeanDirectorJun 09, 2020 Sale$65.819,500625,194549,471Jun 10, 2020, 05:26 PM
Cui Jingrong JeanDirectorJun 08, 2020 Sale$63.4518,5001,173,888566,511Jun 08, 2020, 08:26 PM
Cui Jingrong JeanDirectorJun 05, 2020 Sale$64.2118,5001,187,868583,281Jun 08, 2020, 08:26 PM
Cui Jingrong JeanDirectorJun 04, 2020 Sale$64.8018,5001,198,891603,483Jun 08, 2020, 08:26 PM
George SimeonDirectorMay 21, 2020 Buy$60.0083,3334,999,9802,253,660May 26, 2020, 05:57 PM
Countouriotis AthenaPresident & CEOMay 21, 2020 Buy$60.004,166249,96026,872May 26, 2020, 05:55 PM
GLAXOSMITHKLINE PLCDirectorMay 21, 2020 Buy$60.0083,3334,999,9802,253,660May 26, 2020, 04:17 PM
Cui Jingrong JeanDirectorMay 19, 2020 Sale$57.737,000404,108625,183May 21, 2020, 07:05 PM
Cui Jingrong JeanDirectorMay 21, 2020 Sale$59.657,000417,550605,483May 21, 2020, 07:05 PM
Cui Jingrong JeanDirectorMay 20, 2020 Sale$60.157,000421,045618,883May 21, 2020, 07:05 PM
Cui Jingrong JeanDirectorMay 08, 2020 Sale$53.8611,500619,351637,153May 12, 2020, 08:09 PM
Cui Jingrong JeanDirectorMay 07, 2020 Sale$52.8618,500977,886651,077May 07, 2020, 06:52 PM
Cui Jingrong JeanDirectorMay 06, 2020 Sale$52.9418,500979,323668,811May 07, 2020, 06:52 PM
Cui Jingrong JeanDirectorMay 05, 2020 Sale$54.0218,500999,426689,385May 07, 2020, 06:52 PM
Cui Jingrong JeanDirectorApr 23, 2020 Sale$51.927,000363,408704,183Apr 24, 2020, 08:20 PM
Cui Jingrong JeanDirectorApr 22, 2020 Sale$51.787,000362,481708,683Apr 24, 2020, 08:20 PM
Cui Jingrong JeanDirectorApr 24, 2020 Sale$51.017,000357,090697,170Apr 24, 2020, 08:20 PM
Cui Jingrong JeanDirectorApr 13, 2020 Sale$50.0570835,438714,891Apr 13, 2020, 07:16 PM
Cui Jingrong JeanDirectorApr 09, 2020 Sale$47.4511,500545,648720,609Apr 13, 2020, 07:16 PM
Cui Jingrong JeanDirectorApr 06, 2020 Sale$43.5118,500804,874780,991Apr 08, 2020, 07:21 PM
Cui Jingrong JeanDirectorApr 08, 2020 Sale$46.2518,500855,604738,797Apr 08, 2020, 07:21 PM
Cui Jingrong JeanDirectorApr 07, 2020 Sale$44.8618,500829,998759,091Apr 08, 2020, 07:21 PM
Cui Jingrong JeanDirectorMar 26, 2020 Sale$46.0311,500529,372786,991Mar 27, 2020, 06:27 PM
Cui Jingrong JeanDirectorMar 25, 2020 Sale$45.4217,792808,090809,283Mar 25, 2020, 06:47 PM
Cui Jingrong JeanDirectorMar 24, 2020 Sale$41.957,000293,655817,083Mar 25, 2020, 06:47 PM
Cui Jingrong JeanDirectorMar 23, 2020 Sale$38.397,000268,706824,483Mar 25, 2020, 06:47 PM
Cui Jingrong JeanDirectorMar 11, 2020 Sale$41.2018,500762,202846,183Mar 12, 2020, 08:40 PM
Cui Jingrong JeanDirectorMar 10, 2020 Sale$42.2818,500782,113862,283Mar 12, 2020, 08:40 PM
Cui Jingrong JeanDirectorMar 12, 2020 Sale$36.087,000252,528829,783Mar 12, 2020, 08:40 PM
Cui Jingrong JeanDirectorFeb 24, 2020 Sale$53.707,000375,930884,383Feb 26, 2020, 08:20 PM
Cui Jingrong JeanDirectorFeb 26, 2020 Sale$51.437,000360,014871,983Feb 26, 2020, 08:20 PM
Cui Jingrong JeanDirectorFeb 25, 2020 Sale$51.357,000359,478879,858Feb 26, 2020, 08:20 PM
Cui Jingrong JeanDirectorDec 30, 2019 Option Exercise$5.1216,86486,344890,383Feb 26, 2020, 08:18 PM
Cui Jingrong JeanDirectorDec 27, 2019 Option Exercise$4.7138,080179,456873,519Feb 26, 2020, 08:18 PM
Cui Jingrong JeanDirectorJun 27, 2019 Option Exercise$5.1254,220277,606835,439Feb 26, 2020, 08:18 PM
Cui Jingrong JeanDirectorFeb 13, 2020 Sale$61.8411,500711,137792,519Feb 14, 2020, 04:22 PM
Cui Jingrong JeanDirectorFeb 12, 2020 Sale$65.9218,5001,219,594805,419Feb 12, 2020, 07:31 PM
Cui Jingrong JeanDirectorFeb 11, 2020 Sale$63.2318,5001,169,667815,469Feb 12, 2020, 07:31 PM
Cui Jingrong JeanDirectorFeb 10, 2020 Sale$62.9418,5001,164,482838,968Feb 12, 2020, 07:31 PM
Cui Jingrong JeanChief Scientific OfficerJan 28, 2020 Sale$58.367,000408,529858,151Jan 29, 2020, 07:37 PM
Cui Jingrong JeanChief Scientific OfficerJan 27, 2020 Sale$57.667,000403,652867,620Jan 29, 2020, 07:37 PM
Cui Jingrong JeanChief Scientific OfficerJan 29, 2020 Sale$58.737,000411,104851,820Jan 29, 2020, 07:37 PM
Cui Jingrong JeanChief Scientific OfficerJan 15, 2020 Sale$53.1211,500610,853870,819Jan 17, 2020, 05:10 PM
Cui Jingrong JeanChief Scientific OfficerJan 14, 2020 Sale$53.5618,500990,811895,829Jan 14, 2020, 07:17 PM
Cui Jingrong JeanChief Scientific OfficerJan 13, 2020 Sale$52.8718,500978,073909,813Jan 14, 2020, 07:17 PM
Cui Jingrong JeanChief Scientific OfficerJan 10, 2020 Sale$57.6818,5001,067,161935,919Jan 14, 2020, 07:17 PM
Countouriotis AthenaPresident & CEODec 10, 2019 Option Exercise$31.1370621,97622,706Jan 08, 2020, 04:24 PM
Baker Brian LeeVP of Finance and Admin.Dec 10, 2019 Option Exercise$31.132166,7233,016Jan 08, 2020, 04:12 PM
Cui Jingrong JeanChief Scientific OfficerDec 20, 2019 Sale$63.4011,500729,150946,319Dec 20, 2019, 06:29 PM
Cui Jingrong JeanChief Scientific OfficerDec 19, 2019 Sale$61.0918,5001,130,257964,819Dec 20, 2019, 06:29 PM
Cui Jingrong JeanChief Scientific OfficerDec 18, 2019 Sale$59.2018,5001,095,170980,989Dec 20, 2019, 06:29 PM
Cui Jingrong JeanChief Scientific OfficerDec 13, 2019 Sale$55.7511,500641,1691,019,119Dec 17, 2019, 09:09 PM
Cui Jingrong JeanChief Scientific OfficerDec 17, 2019 Sale$61.3218,5001,134,374999,619Dec 17, 2019, 09:09 PM
Cui Jingrong JeanChief Scientific OfficerDec 16, 2019 Sale$58.3511,500671,0771,014,119Dec 17, 2019, 09:09 PM
Cui Jingrong JeanChief Scientific OfficerDec 12, 2019 Sale$54.1111,500622,2911,037,219Dec 12, 2019, 07:54 PM
Cui Jingrong JeanChief Scientific OfficerDec 11, 2019 Sale$52.9411,500608,7871,040,291Dec 12, 2019, 07:54 PM
Cui Jingrong JeanChief Scientific OfficerDec 10, 2019 Sale$54.5811,500627,6311,058,019Dec 12, 2019, 07:54 PM
Cui Jingrong JeanChief Scientific OfficerDec 05, 2019 Sale$51.9556,1102,914,9361,157,939Dec 09, 2019, 08:44 PM
Cui Jingrong JeanChief Scientific OfficerDec 09, 2019 Sale$55.3211,500636,2291,069,219Dec 09, 2019, 08:44 PM
Cui Jingrong JeanChief Scientific OfficerDec 06, 2019 Sale$50.7750,8902,583,5881,086,482Dec 09, 2019, 08:44 PM
GLAXOSMITHKLINE PLCDirectorSep 10, 2019 Buy$45.00177,7777,999,9652,170,327Sep 12, 2019, 04:18 PM
George SimeonDirectorSep 10, 2019 Buy$45.00177,7777,999,9652,170,327Sep 11, 2019, 06:42 PM
Larson YiEVP & Chief Financial OfficerSep 10, 2019 Buy$45.002,22299,9902,222Sep 11, 2019, 04:16 PM
Countouriotis AthenaPresident & CEOSep 10, 2019 Buy$45.0010,000450,00022,000Sep 11, 2019, 04:15 PM
Cormorant Asset Management, LP10% OwnerMay 14, 2019 Option Exercise$2.1923,26851,0623,122,367May 16, 2019, 04:15 PM
Cormorant Asset Management, LP10% OwnerApr 22, 2019 Buy$18.00400,0007,200,0003,099,099Apr 25, 2019, 04:08 PM
GLAXOSMITHKLINE PLCDirectorApr 22, 2019 Buy$18.00325,0005,850,0001,992,550Apr 24, 2019, 07:28 PM
ORBIMED ADVISORS LLCDirectorApr 22, 2019 Buy$18.00360,0006,480,0002,027,550Apr 24, 2019, 06:16 PM
Lu HongboDirectorApr 22, 2019 Buy$18.0060,0001,080,0001,727,550Apr 24, 2019, 06:11 PM
GORDON CARL LDirectorApr 22, 2019 Buy$18.00360,0006,480,0002,027,550Apr 24, 2019, 06:07 PM
George SimeonDirectorApr 22, 2019 Buy$18.00325,0005,850,0001,992,550Apr 24, 2019, 06:04 PM
Baker Brian LeeVP of Finance and Admin.Apr 22, 2019 Buy$18.002,80050,4002,800Apr 24, 2019, 06:00 PM
Countouriotis AthenaPresident & CEOApr 22, 2019 Buy$18.0012,000216,00012,000Apr 24, 2019, 05:55 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
George SimeonDirector08/17/2022171,278,160
Alles Mark JDirector08/17/2022152,000
TOMBESI PAOLOEVP & Chief Financial Officer08/17/20222,263,128
Hirmand MohammadEVP and Chief Medical Officer08/17/20223,137,584
Countouriotis AthenaPresident & CEO08/17/20228,432,884
TOMBESI PAOLOEVP & Chief Financial Officer07/27/202288,654
Reich SiegfriedEVP & Chief Scientific Officer02/09/202214,411
Partridge Andrew JohnEVP & Chief Commercial Officer02/09/20228,022
North AnnetteEVP & General Counsel02/09/202224,285
Hirmand MohammadEVP & Chief Medical Officer02/09/202224,285
Countouriotis AthenaPresident & CEO02/09/2022107,847
North AnnetteEVP, General Counsel & Secty.08/30/2021170,000
North AnnetteEVP, General Counsel & Secty.08/30/2021800,000
Partridge Andrew JohnEVP & Chief Commercial Officer07/14/2021139,988
Alles Mark JDirector06/21/2021162,680
Baker Brian LeeSVP of Finance and Admin.03/23/2021132,906
Baker Brian LeeSVP of Finance and Admin.03/23/20212,862,082
North AnnetteEVP, General Counsel & Secty.03/08/2021340,000
North AnnetteEVP, General Counsel & Secty.03/08/20212,195,939
Reich SiegfriedEVP & Chief Scientific Officer03/04/20211,823,004
Reich SiegfriedEVP & Chief Scientific Officer03/04/20213,734,075
Countouriotis AthenaPresident & CEO02/11/202128,614
Countouriotis AthenaPresident & CEO02/10/202181,254
Countouriotis AthenaPresident & CEO02/09/202182,131
Countouriotis AthenaPresident & CEO02/11/20211,228,446
Countouriotis AthenaPresident & CEO02/10/20213,461,116
Countouriotis AthenaPresident & CEO02/09/20213,559,475
North AnnetteEVP, General Counsel & Secty.02/02/2021153,272
North AnnetteEVP, General Counsel & Secty.02/01/2021271,728
North AnnetteEVP, General Counsel & Secty.02/02/20211,170,989
North AnnetteEVP, General Counsel & Secty.02/01/20211,976,374
Larson YiEVP & Chief Financial Officer02/01/2021848,379
Larson YiEVP & Chief Financial Officer02/02/2021772,521
Larson YiEVP & Chief Financial Officer02/01/20211,941,105
Larson YiEVP & Chief Financial Officer02/02/20211,860,813
Baker Brian LeeSVP of Finance and Admin.01/07/2021132,918
Baker Brian LeeSVP of Finance and Admin.01/07/20213,819,090
Hirmand MohammadEVP and Chief Medical Officer01/04/2021478,723
Hirmand MohammadEVP and Chief Medical Officer01/05/202168,577
Hirmand MohammadEVP and Chief Medical Officer01/05/2021150,360
Hirmand MohammadEVP and Chief Medical Officer01/04/20211,090,046
Cui Jingrong JeanDirector06/09/2020625,194
Cui Jingrong JeanDirector06/08/20201,173,888
Cui Jingrong JeanDirector06/05/20201,187,868
Cui Jingrong JeanDirector06/04/20201,198,891
George SimeonDirector05/21/20204,999,980
Countouriotis AthenaPresident & CEO05/21/2020249,960
GLAXOSMITHKLINE PLCDirector05/21/20204,999,980
Cui Jingrong JeanDirector05/19/2020404,108
Cui Jingrong JeanDirector05/21/2020417,550
Cui Jingrong JeanDirector05/20/2020421,045
Cui Jingrong JeanDirector05/08/2020619,351
Cui Jingrong JeanDirector05/07/2020977,886
Cui Jingrong JeanDirector05/06/2020979,323
Cui Jingrong JeanDirector05/05/2020999,426
Cui Jingrong JeanDirector04/23/2020363,408
Cui Jingrong JeanDirector04/22/2020362,481
Cui Jingrong JeanDirector04/24/2020357,090
Cui Jingrong JeanDirector04/13/202035,438
Cui Jingrong JeanDirector04/09/2020545,648
Cui Jingrong JeanDirector04/06/2020804,874
Cui Jingrong JeanDirector04/08/2020855,604
Cui Jingrong JeanDirector04/07/2020829,998
Cui Jingrong JeanDirector03/26/2020529,372
Cui Jingrong JeanDirector03/25/2020808,090
Cui Jingrong JeanDirector03/24/2020293,655
Cui Jingrong JeanDirector03/23/2020268,706
Cui Jingrong JeanDirector03/11/2020762,202
Cui Jingrong JeanDirector03/10/2020782,113
Cui Jingrong JeanDirector03/12/2020252,528
Cui Jingrong JeanDirector02/24/2020375,930
Cui Jingrong JeanDirector02/26/2020360,014
Cui Jingrong JeanDirector02/25/2020359,478
Cui Jingrong JeanDirector12/30/201986,344
Cui Jingrong JeanDirector12/27/2019179,456
Cui Jingrong JeanDirector06/27/2019277,606
Cui Jingrong JeanDirector02/13/2020711,137
Cui Jingrong JeanDirector02/12/20201,219,594
Cui Jingrong JeanDirector02/11/20201,169,667
Cui Jingrong JeanDirector02/10/20201,164,482
Cui Jingrong JeanChief Scientific Officer01/28/2020408,529
Cui Jingrong JeanChief Scientific Officer01/27/2020403,652
Cui Jingrong JeanChief Scientific Officer01/29/2020411,104
Cui Jingrong JeanChief Scientific Officer01/15/2020610,853
Cui Jingrong JeanChief Scientific Officer01/14/2020990,811
Cui Jingrong JeanChief Scientific Officer01/13/2020978,073
Cui Jingrong JeanChief Scientific Officer01/10/20201,067,161
Countouriotis AthenaPresident & CEO12/10/201921,976
Baker Brian LeeVP of Finance and Admin.12/10/20196,723
Cui Jingrong JeanChief Scientific Officer12/20/2019729,150
Cui Jingrong JeanChief Scientific Officer12/19/20191,130,257
Cui Jingrong JeanChief Scientific Officer12/18/20191,095,170
Cui Jingrong JeanChief Scientific Officer12/13/2019641,169
Cui Jingrong JeanChief Scientific Officer12/17/20191,134,374
Cui Jingrong JeanChief Scientific Officer12/16/2019671,077
Cui Jingrong JeanChief Scientific Officer12/12/2019622,291
Cui Jingrong JeanChief Scientific Officer12/11/2019608,787
Cui Jingrong JeanChief Scientific Officer12/10/2019627,631
Cui Jingrong JeanChief Scientific Officer12/05/20192,914,936
Cui Jingrong JeanChief Scientific Officer12/09/2019636,229
Cui Jingrong JeanChief Scientific Officer12/06/20192,583,588
GLAXOSMITHKLINE PLCDirector09/10/20197,999,965
George SimeonDirector09/10/20197,999,965
Larson YiEVP & Chief Financial Officer09/10/201999,990
Countouriotis AthenaPresident & CEO09/10/2019450,000
Cormorant Asset Management, LP10% Owner05/14/201951,062
Cormorant Asset Management, LP10% Owner04/22/20197,200,000
GLAXOSMITHKLINE PLCDirector04/22/20195,850,000
ORBIMED ADVISORS LLCDirector04/22/20196,480,000
Lu HongboDirector04/22/20191,080,000
GORDON CARL LDirector04/22/20196,480,000
George SimeonDirector04/22/20195,850,000
Baker Brian LeeVP of Finance and Admin.04/22/201950,400
Countouriotis AthenaPresident & CEO04/22/2019216,000
Load More Insider Transactions
BUYBACK ANNOUNCEMENT(S) FOR TURNING POINT THERAPEUTICS INC
LOADING...